Published in Clinical Trials Week, October 10th, 2005
Researchers from the United States examined the efficacy of "a tumor necrosis factor receptor antagonist (etanercept) in the treatment of chronic ocular sarcoidosis. Eighteen patients with ocular sarcoidosis and ongoing inflammation in the eyes [were studied]."
"All patients had received at least 6 months of therapy with methotrexate and were currently receiving corticosteroids. Patients were randomized to receive either etanercept, 25 mg subcutaneously twice a week, or placebo in a double-blind randomized trial. Treatment for ocular inflammation with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.